Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NCT ID: NCT06967961
Last Updated: 2025-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
450 participants
INTERVENTIONAL
2025-07-23
2029-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer.
450 patients will be enrolled in total.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer
NCT01946672
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
NCT06929013
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn)
NCT06599749
Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer
NCT02838381
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
NCT07267780
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with metastatic cancer
* Blood sample collection for circulating DP cell detection by flow cytometry and Cell Search analysis for the following patients:
* Cohort 1 : urothelial carcinoma
* Cohort 2 : renal carcinoma
* Cohort 3 : prostate adenocarcinoma
* Cohort 4 : upper aerodigestive tract carcinoma
* Cohort 5 : cervical carcinoma
* Cohort 6 : adenocarcinoma of endometrium
* Blood sample collection for circulating DP cell detection by flow cytometry and Parsotix analysis for the following patients:
* Cohort 7 : cutaneous melanoma
* Cohort 8 : soft tissue sarcoma
* Cohort 9 : seminomatous and nonseminomatous germ cell tumors
For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
A blood sample will be taken before initiation of the metastatic treatment line and will be analyzed by 2 distinct methods. The total blood volume withdrawn per patient is approximately 30mL.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Metastatic disease for which the treatment (whatever the line) has not been initiated yet
* 3\. Age ≥ 18 years
* 4\. Patient affiliated to a French Social Security scheme
* 5\. Patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study.
Exclusion Criteria
* 2\. Pregnant or breast-feeding women.
* 3\. Any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol.
* 4\. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Claudius Regaud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncopole Claudius Regaud, IUCT-O
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24GENE19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.